Articles

Invitrogen to sell Nonlinear software

In a move that continues to widen its base of proteomic offerings, Invitrogen Corp. announced that it will distribute a range of advance analysis software solutions from Nonlinear Dynamics, based here. The deal involves a broad selection of Nonlinear products including those for the detailed analysis of 1D and 2D electrophoresis gels.
Written byChris Anderson
| 2 min read

NEWCASTLE-UPON-TYNE, England—In a move that continues to widen its base of proteomic offerings, Invitrogen Corp. announced that it will distribute a range of advance analysis software solutions from Nonlinear Dynamics, based here. The deal involves a broad selection of Nonlinear products including those for the detailed analysis of 1D and 2D electrophoresis gels.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Researcher examining a multiwell plate alongside cell culture dishes in a laboratory.
Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.
Abstract rainbow-colored beams of light spreading across a dark background.
Compare fluorochromes based on resolution, spillover, antigen expression, and other factors that can affect panel performance.
Illustration of multiple glowing blue and purple spherical cells against a dark blue background.
As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.